Core Insights - Dyne Therapeutics plans to provide an update on DYNE-101 for myotonic dystrophy type 1 (DM1) on June 17, 2025, with a webcast scheduled for 8:00 a.m. ET [1] - The company is focused on developing innovative therapeutics for genetically driven neuromuscular diseases, utilizing its FORCE™ platform to enhance delivery to muscle tissue and the central nervous system [3] Company Overview - Dyne Therapeutics is dedicated to discovering and advancing life-transforming therapeutics for individuals with genetically driven neuromuscular diseases [3] - The company has a diverse pipeline that includes clinical programs for DM1 and Duchenne muscular dystrophy (DMD), as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD) [3] Investor Engagement - A live webcast of the update will be available on Dyne's website, with a replay accessible for 90 days post-presentation [2] - An accompanying slide presentation will also be provided during the webcast [2]
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET